ASCO Highlights 2024

from the beginning

ASCO Highlights 2024

Forward-Looking Statements

ASCO Highlights 2024: IR conference call

Agenda

1 Welcome message

2 R&D strategy

ASCO 2024

Establish and expand DXd ADCs to address the broader spectrum of Breast Cancer

Establish and expand DXd ADCs to address the broader spectrum of Lung Cancer

TROPION-Lung15 study

3 Highlights from ASCO 2024

Trastuzumab deruxtecan

DESTINY-Breast06: key takeaways

Unmet treatment need in HR+, HER2-negative mBC

Targeting ‘low’ and ‘ultralow’ HER2-expressing tumors in mBC

Study design

Patient disposition

Patient demographics and key baseline characteristics

Prior therapies

PFS (BICR) in HER2-low: primary endpoint

PFS (BICR) in ITT: key secondary endpoint

OS in HER2-low and ITT: key secondary endpoints (~40% maturity)

PFS and OS in HER2-ultralow: prespecified exploratory analyses

PFS (BICR) in HER2-low: subgroup analysis

Antitumor activity

Overall safety summary

Drug-related TEAEs in 20% of patients (either treatment group)

Adverse events of special interest

Conclusions

Poster #1025

@

@

DESTINY-Breast07: dose-expansion analysis of TDXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC

Study background and rationale

Study design

Baseline characteristics

Patient disposition

Response to treatment per RECIST 1.1 by investigator

Duration of response

cORR and BOR by subgroup per RECIST 1.1 by investigator

Safety overview

Conclusions

Poster #8543

@

@

@

Poster #8617

@

@

@

@

4 Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7